Toward personalized synchrotron microbeam radiation therapy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
27
11
2019
accepted:
08
05
2020
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
27
11
2020
Statut:
epublish
Résumé
Synchrotron facilities produce ultra-high dose rate X-rays that can be used for selective cancer treatment when combined with micron-sized beams. Synchrotron microbeam radiation therapy (MRT) has been shown to inhibit cancer growth in small animals, whilst preserving healthy tissue function. However, the underlying mechanisms that produce successful MRT outcomes are not well understood, either in vitro or in vivo. This study provides new insights into the relationships between dosimetry, radiation transport simulations, in vitro cell response, and pre-clinical brain cancer survival using intracerebral gliosarcoma (9LGS) bearing rats. As part of this ground-breaking research, a new image-guided MRT technique was implemented for accurate tumor targeting combined with a pioneering assessment of tumor dose-coverage; an essential parameter for clinical radiotherapy. Based on the results of our study, we can now (for the first time) present clear and reproducible relationships between the in vitro cell response, tumor dose-volume coverage and survival post MRT irradiation of an aggressive and radioresistant brain cancer in a rodent model. Our innovative and interdisciplinary approach is illustrated by the results of the first long-term MRT pre-clinical trial in Australia. Implementing personalized synchrotron MRT for brain cancer treatment will advance this international research effort towards clinical trials.
Identifiants
pubmed: 32483249
doi: 10.1038/s41598-020-65729-z
pii: 10.1038/s41598-020-65729-z
pmc: PMC7264143
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8833Références
von Neubeck, C., Seidlitz, A., Kitzler, H. H., Beuthien-Baumann, B. & Krause, M. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs. Br. J. Radiol. 88(1053), 20150354 (2015).
doi: 10.1259/bjr.20150354
Sizoo, E. M. et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. J. Neurooncol 12, 1162–1166 (2010).
GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 376–393 (2019).
doi: 10.1016/S1474-4422(18)30468-X
Slatkin, D. N., Spanne, P., Dilmanian, F. A. & Sandborg, M. Microbeam radiation therapy. Med. Phys. 19, 1395 (1992).
pubmed: 1461201
doi: 10.1118/1.596771
Blattmann, H. et al. Applications of synchrotron X-rays to radiotherapy. Nucl. Instrum. Methods Phys. Res. A 548, 17–22 (2005).
doi: 10.1016/j.nima.2005.03.060
Bouchet, A. et al. Synchrotron microbeam radiation therapy induces hypoxia in intracerebral gliosarcoma but not in the normal brain. Radiother. Oncol. 108, 143–148 (2013).
pubmed: 23731617
doi: 10.1016/j.radonc.2013.05.013
Laissue, J. et al. Weanling piglet cerebellum: a surrogate for tolerance to MRT (microbeam radiation therapy) in pediatric neuro-oncology. Proc SPIE. 4508, Penetrating Radiation Systems and Applications III; (2001).
Laissue, J. A., Blattmann, H., Wagner, H. P., Grotzer, M. A. & Slatkin, D. N. Prospects for microbeam radiation therapy of brain tumours in children to reduce neurological sequelae. Dev. Med. Child. Neurol. 49, 577e81 (2007).
doi: 10.1111/j.1469-8749.2007.00577.x
Laissue, J. A. et al. Neuropathology of ablation of rat gliosarcomas and contiguous brain tissues using a microplanar beam of synchrotron-wiggler-generated x rays. Int. J. Cancer. 78, 654–660 (1998).
pubmed: 9808538
doi: 10.1002/(SICI)1097-0215(19981123)78:5<654::AID-IJC21>3.0.CO;2-L
Laissue, J. A. et al. Microbeam radiation therapy. Proc. SPIE 3770, 38–45 (1999).
doi: 10.1117/12.368185
Smilowitz, H. M. et al. Synergy of gene-mediated immunoprophylaxis and microbeam radiation therapy for advanced intracerebral rat 9L gliosarcomas. J. Neurooncol. 78, 135–143 (2006).
pubmed: 16598429
doi: 10.1007/s11060-005-9094-9
Serduc, R. et al. Synchrotron microbeam radiation therapy for rat brain tumor palliation-influence of the microbeam width at constant valley dose. Phys. Med. Biol. 54, 6711–24 (2009).
pubmed: 19841517
doi: 10.1088/0031-9155/54/21/017
Bouchet, A. et al. Preferential Effect of Synchrotron Microbeam Radiation Therapy on Intracerebral 9l gliosarcoma Vascular Networks. Int. J. Radiat. Oncol. Biol. Phys. 78, 1503–1512 (2010).
pubmed: 20932689
doi: 10.1016/j.ijrobp.2010.06.021
Dilmanian, F. A. et al. Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. Neuro Oncol. 4, 26–38 (2002).
pubmed: 11772430
pmcid: 1920629
doi: 10.1215/15228517-4-1-26
Regnard, P. et al. Irradiation of intracerebral 9L gliosarcoma by a single array of microplanar x-ray beams from a synchrotron: balance between curing and sparing. Phys. Med. Biol. 53, 861–878 (2008).
pubmed: 18263945
doi: 10.1088/0031-9155/53/4/003
Le Duc, G. et al. Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. ACS Nano. 5, 9566–74 (2011).
pubmed: 22040385
doi: 10.1021/nn202797h
Smyth, L. M., Senthi, S., Crosbie, J. C. & Rogers, P. A. The normal tissue effects of microbeam radiotherapy: What do we know, and what do we need to know to plan a human clinical trial? Int. J. Radiat. Biol. 92, 302–11 (2016).
pubmed: 26982077
doi: 10.3109/09553002.2016.1154217
Smyth, L. M., Rogers, P. A. W., Crosbie, J. C. & Donoghue, J. F. Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro. Radiat. Res. 189, 146–155 (2018).
pubmed: 29364085
doi: 10.1667/RR4633.1
Yang, Y. et al. In vitro study of genes and molecular pathways differentially regulated by synchrotron microbeam radiotherapy. Radiat. Res. 182, 626–39 (2014).
pubmed: 25409126
doi: 10.1667/RR13778.1
Barbone, G. E. et al. Micro-imaging of brain cancer radiotherapy using phase-contrast computed tomography. Int. J. Radiat. Oncol. Biol. Phys. 101, 965–984 (2018).
pubmed: 29976510
doi: 10.1016/j.ijrobp.2018.03.063
Smyth, L. M. L. et al. Comparative toxicity of synchrotron and conventional radiation therapy based on total and partial body irradiation in a murine model. Sci. Rep. 8, 12044 (2018).
pubmed: 30104646
pmcid: 6089899
doi: 10.1038/s41598-018-30543-1
Potez, M. et al. Effects of Synchrotron X-Ray Micro-beam Irradiation on Normal Mouse Ear Pinnae. Int. J. Radiat. Oncol. Biol. Phys. 101, 680–689 (2018).
pubmed: 29559293
doi: 10.1016/j.ijrobp.2018.02.007
Schültke, E. et al. Memory and survival after microbeam radiation therapy. Eur. J. Radiol. 68(3 Suppl), 142–6 (2008).
doi: 10.1016/j.ejrad.2008.04.051
Fardone, E. et al. Rat sensorimotor cortex tolerance to parallel transections induced by synchrotron-generated X-ray microbeams. Sci. Rep. 7, 14290 (2017).
pubmed: 29085040
pmcid: 5662592
doi: 10.1038/s41598-017-14757-3
Stevenson, A. W. et al. Quantitative characterization of the X-ray beam at the Australian Synchrotron Imaging and Medical Beamline (IMBL). J. Synchrotron Radiat. 24, 110–141 (2017).
pubmed: 28009552
doi: 10.1107/S1600577516015563
Dipuglia, A. et al. Validation of a Monte Carlo simulation for Microbeam Radiation Therapy on the Imaging and Medical Beamline at the Australian Synchrotron. Sci. Rep. 9, 17696 (2019).
pubmed: 31776395
pmcid: 6881291
doi: 10.1038/s41598-019-53991-9
Petasecca, M. et al. X-Tream: a novel dosimetry system for Synchrotron Microbeam Radiation Therapy. J. Instrum. 7, 1–15 (2012).
doi: 10.1088/1748-0221/7/07/P07022
Fournier, P. et al. X-Tream dosimetry of highly brilliant X-ray microbeams in the MRT hutch of the Australian Synchrotron. Radiat. Meas. 106, 405–411 (2017).
doi: 10.1016/j.radmeas.2017.01.011
Davis, J. A. et al. Characterisation and evaluation of a PNP strip detector for synchrotron microbeam radiation therapy. Biomed. Phys. Eng. Express. 4, 044002 (2018).
doi: 10.1088/2057-1976/aab10c
Cameron, M. et al. Comparison of phantom materials for use in quality assurance of microbeam radiation therapy. J. Synchrotron Radiat. 24(4), 866–876 (2017).
pubmed: 28664894
doi: 10.1107/S1600577517005641
Davis, J. A. et al. X-Tream dosimetry of synchrotron radiation with the PTW microdiamond. J. Instrum. 14, P10037–P10037 (2019).
doi: 10.1088/1748-0221/14/10/P10037
Meena, U. S., Sharma, S., Chopra, S. & Jain, S. K. Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. World J. Clin. Cases 4, 302–305 (2016).
pubmed: 27672648
pmcid: 5018630
doi: 10.12998/wjcc.v4.i9.302
National Health and Medical Research Council. Australian code for the care and use of animals for scientific purposes, 8th edition. Canberra: National Health and Medical Research Council (2013).
Cunliffe-Beamer, T. Surgical Techniques. Guidelines for the Well Being of Rodents in Research. Bethesda, Maryland, Scientists Center for Animal Welfare. 86–92, (1990).
Pritchett-Corning, K. R., Mulder, G. B., Luo, Y. & White, W. J. Principles of Rodent Surgery for the New Surgeon. J. Vis. Exp. 47, e2586 (2011).
Barnes, M. A patient-positioning system for synchrotron micro-beam radiotherapy (MRT), Masters by Research, Science, RMIT University URL, http://researchbank.rmit.edu.au/view/rmit:162679 (2018).
Ian, S. Kwan et al. Skin dosimetry with new MOSFET detectors. Radiat. Meas. 43(2–6), 929–932 (2008).
MATLAB and Statistics Toolbox Release 2012b, The MathWorks, Inc., Natick, Massachusetts, United States., https://www.mathworks.com/products/matlab.html .
Vozenin, M. C. et al. Biological Benefits of Ultra-high Dose Rate FLASH Radiotherapy: Sleeping Beauty Awoken. Clin. Oncol. 31, 407–415 (2019).
doi: 10.1016/j.clon.2019.04.001
Niemierko, A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med. Phys. 24, 103–110 (1997).
pubmed: 9029544
doi: 10.1118/1.598063
Minaei, E. et al. PO-437 Drug and radio sensitivity profile of a primary CTC cell line derived from a patient with metastatic neuroendocrine tumour of the distal oesophagus. ESMO Open. 3(Suppl 2), A1–A463 (2018).
Yaromina, A., Krause, M. & Baumann, M. Individualization of cancer treatment from radiotherapy perspective (012). Mol. Oncol. 6, 211–221 (2012).
pubmed: 22381063
pmcid: 5528361
doi: 10.1016/j.molonc.2012.01.007
Trott, K. R. Can tumour response be assessed from a biopsy? Br. J. Cancer Suppl. 4, 163–70 (1980).
pubmed: 7000119
pmcid: 2149267
Zahra, M. A. et al. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol. 8, 63–74 (2007).
pubmed: 17196512
doi: 10.1016/S1470-2045(06)71012-9
Hung, A. L. et al. Biomarkers and immunotherapeutic targets in glioblastoma. World Neurosurg. 102, 494–506 (2017).
pubmed: 28300714
doi: 10.1016/j.wneu.2017.03.011
Goswami, S. et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat. Med. 26, 39–46 (2020).
pubmed: 31873309
doi: 10.1038/s41591-019-0694-x
Engels, E. et al. Thulium Oxide Nanoparticles: A new candidate for image-guided radiotherapy. Biomed. Phys. Eng. Express 4, 044001 (2018).
doi: 10.1088/2057-1976/aaca01
Engels, E. et al. Synchrotron activation radiotherapy: Effects of dose-rate and energy spectra to tantalum oxide nanoparticles selective tumour cell radiosensitization enhancement. J. Phys. Conf. Ser. 777, 1–4 (2016).
Bräuer-Krisch, E. et al. New irradiation geometry for microbeam radiation therapy. Phys. Med. Biol. 50, 3103–11 (2005).
pubmed: 15972983
doi: 10.1088/0031-9155/50/13/009
Régnard, P. et al. Enhancement of survival of 9L gliosarcoma bearing rats following intracerebral delivery of drugs in combination with microbeam radiation therapy. Eur. J. Radiol. 68S, S151–S155 (2008).
doi: 10.1016/j.ejrad.2008.04.049
Bouchet, A. Characterization of the 9L gliosarcoma implanted in the Fischer rat: an orthotopic model for a grade IV brain tumor. Tumor Biol. 35, 6221–6233 (2014).
doi: 10.1007/s13277-014-1783-6
Albrecht, M., Henke, J., Tacke, S., Markert, M. & Guth, B. Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolamand fentanyl on physiological variables continuously measured by telemetry in Wistar rats. BMC Vet. Res. 10, 198 (2014).
pubmed: 25149627
pmcid: 4363998
doi: 10.1186/s12917-014-0198-3
Jordan, B. F. & Sonveaux, P. Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy. Front. Pharmacol. 3, 94 (2012).
pubmed: 22661950
pmcid: 3357106
doi: 10.3389/fphar.2012.00094